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Abstract
Background: There are inconsistencies in the literature regarding the prevalence and assessment of chemotherapy-
induced peripheral neuropathy (CIPN). This study explored CIPN natural history and its characteristics in patients
receiving taxane- and platinum-based chemotherapy.
Patients and methods: Multi-country multisite prospective longitudinal observational study. Patients were assessed
before commencing and three weekly during chemotherapy for up to six cycles, and at 6,9, and 12 months using
clinician-based scales (NCI-CTCAE; WHO-CIPN criterion), objective assessments (cotton wool test;10 g monofilament);
patient-reported outcome measures (FACT/GOG-Ntx; EORTC-CIPN20), and Nerve Conduction Studies.
Results: In total, 343 patients were recruited in the cohort, providing 2399 observations. There was wide variation in
CIPN prevalence rates using different assessments (14.2–53.4%). Prevalence of sensory neuropathy (and associated
symptom profile) was also different in each type of chemotherapy, with paclitaxel (up to 63%) and oxaliplatin (up to
71.4%) showing the highest CIPN rates in most assessments and a more complex symptom profile. Peak prevalence
was around the 6-month assessment (up to 71.4%). Motor neurotoxicity was common, particularly in the docetaxel
subgroup (up to 22.1%; detected by NCI-CTCAE). There were relatively moderately-to-low correlations between scales
(rs = 0.15,p < 0.05-rs = 0.48 p < 0.001), suggesting that they measure different neurotoxicity aspects from each other.
Cumulative chemotherapy dose was not associated with onset and course of CIPN.
Conclusion: The historical variation reported in CIPN incidence and prevalence is possibly confounded by
disagreement between assessment modalities. Clinical practice should consider assessment of motor neuropathy for
neurotoxic chemotherapy. Current scales may not be all appropriate to measure CIPN in a valid way, and a
combination of scales are needed.
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Background
Chemotherapy- induced peripheral neuropathy (CIPN)
is one of the major dose-limiting side effects of many
chemotherapeutic agents including platinum ana-
logues, vinca alkaloids, and taxanes [1]. The structure
and function of peripheral motor, sensory and
autonomic neurons are affected, causing peripheral
neuropathic signs and symptoms [2]. In a systematic
review of 31 studies (N = 4179), CIPN prevalence was
68.1% at the first month of chemotherapy to 30%
six-months after chemotherapy, with wide variance in
prevalence from 12.1–96.2%, depending on different
timings of assessment and type of chemotherapy, and
many assessing CIPN as part of a drug trial or with
studies being cross-sectional [3].
What is already known is that neuropathic symptoms
tend to progress during chemotherapy and generally re-
gress once treatment stops; symptoms can consist of a
mixture of motor, sensory, and autonomic signs; and the
pain associated with CIPN can be prolonged and severe,
and its treatment is usually difficult [3–5]. Furthermore,
neuropathy can have a negative impact on patient’s qual-
ity of life [4]. Studies showed that CIPN is associated
with fatigue, psychological distress and decline in phys-
ical independence [6–10]. CIPN may have an impact on
the patients’ ability to work [11] and is associated with
significantly higher medical costs ($17,344 more/patient)
and higher healthcare utilization than non-CIPN pa-
tients [12].
It is clear in the literature that the assessment of
CIPN is suboptimal [6]. A recent study using a
Delphi technique in a small number of clinicians and
consumers showed that there is no consensus as to
the best assessment method for CIPN [13]. The NCI
Common Toxicity Criteria (CTC) assessment for
neuropathy may overestimate the presence of motor
neuropathy and misdiagnose CIPN [14], although a
consensus meeting suggested that the NCI CTC has
good intra/interrater scores and validity [15]. Haryani
et al. [16] reviewed available scales and suggested that
the FACT-COG-Ntx scale and the Total Neuropathy
Scale (TNS) as psychometrically optimal scales out of
20 tools examined. In another study, the Patient
Neurotoxicity Questionnaire (PNQ) and the TNS were
recommended [13]. The PNQ in particular seems to
have received extensive evaluation in response to
identified assessment problems with high variance and
lack of reliability and concordance of past scales [1,
17–20], and was recommended as a patient-reported
outcome preferred tool by another study [13]. It is
also clear that there is a significant discrepancy be-
tween clinician-rated CIPN through available tools
and patient-reported outcome scales, with clinicians
under-estimating the severity of CIPN [19]. Another
study showed that EORTC-CIPN20 scores may not be
reliably converted to CTCAE scores [21]. While the
NCI CTC score is generally considered unreliable [6],
it has shown significant correlations with the more
accepted and reliable TNS [22]. There are multiple
studies on this topic, all providing different and often
contradictory views on the most appropriate CIPN as-
sessment method, with no ‘gold standard’ consensus
being reached yet.
Longitudinal studies to systematically determine the
incidence, severity and natural history of CIPN with
different neurotoxic chemotherapy drugs are vital in
order to quantify the extent of the problem and in-
form future design of interventional studies; such
studies are uncommon in the literature [23]. Also,
prevalence may be linked with the particular assess-
ment scale used in each study, and the sensitivity of
scales to detect CIPN is variable in the literature.
While some assessment tools have received significant
attention in the literature (most with variable reliabil-
ity/validity issues as mentioned above), there may be
other tools that can be utilised in the assessment of
CIPN and have received minimal attention that are
however used in other areas of medicine effectively
(ie. in assessing diabetic neuropathy, etc). Hence, the
present study aims to identify the natural history and
progression of CIPN within different chemotherapy
drugs for up to 12 months after the patient’s first in-
fusion of chemotherapy and to analyse consistency of
different assessment methods, including the introduc-
tion of some more novel approaches in CIPN assess-
ment in detecting prevalence.
Methods
Design
Multinational prospective longitudinal observational
cohort study over 12 months from the patient’s first
neurotoxic chemotherapy infusion.
Sample and settings
The sample included a heterogeneous group of consecu-
tive patients receiving neurotoxic chemotherapy as inpa-
tients or outpatients in three large hospitals in Hong
Kong, Singapore, and Manchester, UK.
Inclusion criteria
 Cancer patients who are neurotoxic chemotherapy-
naïve and about to receive taxane- and/or platinum-
based chemotherapy
 estimated survival of at least 12 months (as judged
by the clinicians)
 aged 18+ years
 able to give written informed consent
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Sampling and procedures
Eligible patients were identified by convenient sam-
pling and were approached at the outpatients’ clinics
by a designated researcher consecutively if they met
inclusion criteria. Patients were provided with detailed
information about the study. Those who agreed to
participate and provided signed consent completed all
the baseline measurements and CIPN toxicity assess-
ment at different time intervals. The researchers who
carried out the toxicity assessments had undertaken
training in neurological assessments beforehand and
were provided with a set of standardized guiding
questions regarding the grade of toxicity, in order to
maintain consistency. Clinical data were obtained
from the patients’ medical records. The study was ap-
proved by all participating hospitals and their respect-
ive ethics committees.
Outcome measures
All assessments were carried out at baseline, at the
end of each chemotherapy cycle (before or on day 1
of each chemotherapy cycle) for up to six cycles, and
at 6, 9 and 12 months after enrollment into the study.
The NCI-CTCAE is a clinician-based grading system
that includes criteria and definitions for quantifying the
severity of CIPN in both sensory and motor compo-
nents, utilizing a 5-point scale [grade 1 (asymptomatic)
to grade 5 (death)]. A score of >/=2 was deemed indica-
tive of CIPN.
The WHO-CIPN criterion is also a clinician-based
grading system, which includes paresthesias, reflex de-
creases and extent of motor loss as parameters [24], with
scores from 0 (none) to 4 (paralysis). A score of >/=1
was deemed indicative of CIPN.
Additionally, a neurological examination (deep ten-
don reflexes; pin sensation; strength) supplemented
with a list of questions as mentioned earlier were also
used to derive to the scoring of the above two scales.
Sensory examination was conducted by a research
team member using: a) cotton wool to lightly touch the
patient’s hands and feet bilaterally with the patients eyes
closed at five points in each limb and b) 10 g monofila-
ment test in five points in each limb which is a com-
monly used test in detecting diabetic neuropathy [25].
Hypo/hyperesthesia in most points touched was deemed
indicative of CIPN.
Patient-reported outcome measures: For the current
analysis, only the four items on numbness/tingling in
hands/feet were used from the neuropathy modules of:
a) The Functional assessment of cancer therapy (FACT/
GOG-Ntx) [26, 27]. b) The EORTC-QLQ-C30 with its
CIPN20 module [28].
Of the main study cohort, a sub-group of patients con-
sented to nerve conduction studies (NCS) as a mode of
measurement of CIPN. Each patient underwent NCS of
the upper and lower limbs for assessment of neuropathy
at three time points: before (NCSbaseline), at the end of
treatment (NCSend) and 3 months post-treatment
(NCS3m). Sensory nerve action potential (SNAP) ampli-
tudes and conduction velocities were measured in the
bilateral medial, ulnar and radial nerves [29]. Compound
motor action potential (cMAP) amplitudes and motor
nerve conduction velocities were evaluated in the bilat-
eral sural, saphenous, superficial peroneal, common
peroneal and tibial nerves [30].
Data analysis
Descriptive statistics were used to summarise the data.
Prevalence estimates were calculated using 95% CIs of
the percentage of patients with CIPN. Spearman corre-
lations were used to examine the interrelationships
among CTCAE-sensory, CTCAE-motor, monofilament,
and WHO criterion. The dose-response relationships
between cumulative chemotherapy dose and CIPN were
visualized using restricted cubic splines, and the exact
dose-response equations were estimated using seg-
mented regression models. The dose-response relation-
ship analysis was performed using R3.3.0 and the
remaining statistical analysis was performed using SPSS
v.23.0.
Results
Sample characteristics
The sample included 343 patients being assessed up to
a maximum of 10 times over 12 months (total = 2399
assessments); 213 were recruited from Hong Kong, 94
from Singapore and 36 from Manchester, UK. They
were at a mean age of 55.15 years old (SD = 9.4;
range = 33–79). Furthermore, 33 subjects completed
the NCSbaseline and NCSend assessments, out of which
22 also completed the NCS3m. Among the patients
who completed the NCS, 28 were female (85%), at a
median age of 54 years and were receiving primarily
Taxol (85%) and platinum-based chemotherapy (15%).
Other overall sample characteristics are shown in
Table 1.
Prevalence of CIPN
CIPN prevalence rates identified by different measure-
ment tools varied significantly, and occurrence of CIPN
peaked at different times. CIPN peak prevalence rates
were 17.5% for the CTCAE motor criterion and 14.2%
for the CTCAE sensory criterion at cycle 6; 30.3% for
the WHO criterion at cycle 5; 13.4% for the cotton wool
test at 6-month follow-up; 19.4% for the monofilament
test at 6-month follow-up; 44.9–53.4% for the
EORTC-CIPN20 items at cycle 6, and 46.3–49.6% at
cycle 6 and 6-month follow-up (Table 2 and Fig. 1).
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Motor symptoms were slightly more frequently reported
than sensory symptoms (as per CTCAE).
In the taxane-based group, there was a sharp in-
crease soon into the 3rd-5th chemotherapy cycles,
and rates remained high across subsequent follow-up,
with only a noticeable decrease at the 12-month
follow-up (Fig. 2). and peak rates ranging, depending
on the scale used, from 13.1% (cotton wool; 9MFU),
19.5% (CTCAE-sensory, 6MFU), 20.3% (CTCAE-mo-
tor, 6MFU), 32.2% (WHO, cycle5), 43.1–47.2%
(FACT/COG-Ntx, 6MFU) to 42.3–54.9% (EORTC,
cycle 6 & 6MFU). In the platinum-based group, CIPN
levels were relatively low, often being established very
early (cycles 2–3) (Fig. 3). In the combination groups,
noticeable increases were around cycles 3–6, decreas-
ing significantly after the 6-month follow-up (Fig. 4).
Severe CIPN scores (ie. >/=3 in CTCAE; >/=2 in
WHO scale) accounted for a very small number
(highest 3.9%) of patients at 6-month follow-up, al-
though this was up to 22.9% at cycle 6 using the
EORTC-CIPN20 numbness item (hands/fingers).
Within chemotherapy categories, different chemo-
therapy types produced differential neurotoxicity. In
the taxane group, motor dysfunction was more preva-
lent in the docetaxel subgroup with a steady increase
over cycles, with highest prevalence at 9 months
(21.3%), whereas the paclitaxel subgroup showed sig-
nificantly lower prevalence (Table 3 & Fig. 5a-f ). The
opposite was true for sensory dysfunction, where the
paclitaxel subgroup had substantially higher rates of
sensory problems than the docetaxel subgroup, and at
times of certain assessments the difference was 5–10
times more (Table 3 & Fig. 5a-f ). When paclitaxel
was combined with carboplatin, again the rates of
CIPN were significantly higher in this subgroup than
docetaxel plus carboplatin (Table 3 & Fig. 5a-f ). The
prevalence varied significantly from scale to scale
used for the assessment. From the clinician-based
assessment (supplemented by neurological examin-
ation), highest prevalence was identified with the
WHO-CIPN item followed by the use of monofila-
ment. The patient-reported outcome measures showed
significantly higher prevalence than any clinician-
based measures; to note, these scales, unlike the
clinician-based ones, also showed a considerable num-
ber of patients who reported symptoms indicative of
CIPN at the baseline assessment (3.2–21.4%) (Table 3
& Fig. 5a-f ). Looking at the PRO descriptors of CIPN
(using the 9-month assessment, with all other assess-
ments being very similar), typically patients with pac-
litaxel or oxaliplatin had a higher incidence than
other protocols in terms of tingling in the hands/fin-
gers (42.9 and 47.1% respectively vs 3.6–14.4%); tin-
gling in the feet/toes (42.9 and 52.9% respectively vs
0–15.6%); burning pain in hands/feet/fingers/toes
(23.8 and 23.5% respectively vs 0–9.5%); dizziness (19
and 17.6% respectively vs 3.6–8.9%); or blurred vision
(38.1 and 35.3% respectively vs 10.7–27.8%). Cramps
in the hands were more common in the carboplatin/
cisplatin subgroup (19 and 23.5% respectively) while
cramps in the feet were more common in the pacli-
taxel (28.6%) and oxaliplatin (29.4%) subgroup.
Table 1 Socio-demographic and clinical characteristics of the
participants (N = 343)
Characteristic N %
Sex
Male 87 25.4
Female 256 74.6
Ethnicity
Chinese 269 78.4
Non-Chinese Asian 31 9.0
Caucasian 43 12.5
Cancer diagnosis
Breast cancer 174 50.7
Lung cancer 48 14.0
Gynecological cancer 46 13.4
Head & Neck cancer 30 8.7
Gastrointestinal cancer 29 8.5
Urinary tract cancer 16 4.7
Cancer stage
I 52 15.2
II 99 28.9
III 116 33.8
IV 76 22.2
Treatment intent
Curative 250 72.9
Definitive 30 8.7
Palliative 63 18.4
Type of chemotherapy
Taxane 155 45.2
Platinum 109 31.8
Combination of taxane plus platinum 79 23.0
Chemotherapy protocol
Docetaxel 122 35.6
Paclitaxel 33 9.7
Cisplatin/Carboplatin 80 23.4
Oxaliplatin 28 8.3
Carboplatin+Paclitaxel 49 14.4
Carboplatin+Docetaxel 29 8.6
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Hearing problems were reported more often in the
cisplatin/carboplatin subgroup (28.6%). Maintaining
erection was reported primarily by the docetaxel sub-
group (85.7%) and carboplatin/cisplatin subgroup
(50%).
Cumulative chemotherapy dose and CIPN
Figures 6a-e show the dose-response relationship in dif-
ferent chemotherapy agents. No relationship was found
for CIPN increases relative to the agent’s cumulative
dose (Table 4). In most agents CIPN was established
early in the treatment and continued to increase or
remained relatively stable irrespective of the cumulative
dose. This analysis was followed by a segmented regres-
sion for each chemotherapy agent, and again this
showed no cumulative dose relationship with CIPN, with
the exception of cisplatin-based regimens (=362 observa-
tions). In the latter, the turning point for motor CIPN
(using CTCAE) was a dose of 249 mg/m2 (p < 0.001)
and for sensory CIPN was 234 mg/m2 (p < 0.05), with
lower cumulative dose than the turning point being
linked with lower CIPN, and higher cumulative dose
than the turning point not being associated with any
higher CIPN.
Correlations between scales
Among the four clinician-based diagnostic scales, correla-
tions were moderate to low at best. Often scales were not
correlated with each other, and they were showing some-
what stronger correlations in later assessments, when CIPN
was more well-established. The WHO criterion had corre-
lations of rs = 0.21–0.37 (p < 0.001) with the other scales at
baseline and highest at 9-month (rs = 0.44–0.65, p < 0.001)
and 12-month (rs = 0.40–0.59, p < 0.001) assessment. The
WHO criterion was correlated more with the (sensory)
monofilament assessment (rs = 0.21–0.68, p < 0.001) and had
low to moderate correlations (rs = 0.15, p < 0.05 - rs = 0.48,
p < 0.001) with the sensory CIPN CTCAE.
Nerve conduction study (NCS)
Patients treated with taxane chemotherapy showed a
substantial decrease in SNAP (sensory) amplitudes at
NCSend (35.52 ± 4.48% lesser compared to NCSbaseline).
Specifically, the SNAP amplitudes of the upper limbs
were affected nearly twice as much as the lower limbs
(42.79 ± 3.90% and 26.71 ± 8.45% lower than NCSbaseline,
respectively). In contrast, the cMAP (motor) amplitudes
of the lower limbs showed substantial decrease at
NCSend, compared to the upper limbs (17.42 ± 6.51%
and 1.87 ± 2.23% lower than NCSbaseline, respectively).
Compared to the amplitudes, the sensory and motor vel-
ocities displayed a minor decrease at NCSend (1.54 ± 2.52%
and 2.05 ± 1.63% lower than NCSbaseline, respectively)
(Fig. 7).
At 3months post chemotherapy, i.e. NCS3m, patients
continued to demonstrate a large decrease in SNAP am-
plitudes (a further decrease of 7.79 ± 7.05% lower than
NCSend). It is to be noted that the upper limbs (4.85 ±
8.15% lower than NCSend) had better recovery compared
to the lower limbs (18.33 ± 13.97% lower than NCSend).
Fig. 1 Chemotherapy-induced peripheral neuropathy prevalence by different measures over 1-year period
Molassiotis et al. BMC Cancer          (2019) 19:132 Page 7 of 19
Fig. 2 Chemotherapy-induced peripheral neuropathy (with 95% CIs)
over time and with different measures used in patients
receiving taxanes
Fig. 2 (Continued)
Molassiotis et al. BMC Cancer          (2019) 19:132 Page 8 of 19
Fig. 3 Chemotherapy-induced peripheral neuropathy (with 95% CIs)
over time and with different measures used in patients receiving
platinum chemotherapy
Fig. 3 (Continued)
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Fig. 4 Chemotherapy-induced peripheral neuropathy (with 95% CIs)
over time and with different measures used in patients receiving
combination chemotherapy with taxanes and platinum
Fig. 4 (Continued)
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On the other hand, the SNAP velocities had negligible im-
provement (0.69 ± 2.78% lower than NCSend). The cMAP
amplitudes, showed a recovery at NCS3m (4.34 ± 3.05%
higher than NCSend). The upper limbs did not exhibit
much change (0.48 ± 2.03% lower than NCSend), while the
lower limbs showed a considerable increase in NCS value
(39.41 ± 16.28% higher than NCSend). Similar to the
NCS3m trend of the SNAP amplitudes, the motor veloci-
ties suffered a large deterioration (8.24 ± 3.91% lower than
NCSend), with the upper limbs (6.54 ± 3.99% lower than
NCSend) better than the lower limbs (20.28 ± 14.07% com-
pared to lower than NCSend) (Fig. 7).
Discussion
The current study is the largest and one of a few lon-
gitudinal assessments of CIPN (2399 observations)
using a heterogeneous population that increases the
generalizability of the results. It showed that preva-
lence was significantly different from measure to
measure used, patient reported outcome measures
(through quality of life scales) consistently showed
much higher CIPN rates than clinician-based or ob-
jective measures, and with highest rates in patients
receiving taxanes (primarily paclitaxel). Cumulative
dose was not linked with higher CIPN prevalence, but
time since starting chemotherapy was. Correlations
among scales were generally low, although these in-
creased in the later assessments primarily among sen-
sory neuropathy assessments. NCS data confirmed the
sensory and motor impairment of participants.
This study confirms that there is wide variation of CIPN
prevalence between scales. This is supported by a
meta-analysis of CIPN prevalence studies, where confi-
dence intervals were high (i.e. at 3 months CIs = 37–84%)
[3]. CIPN prevalence is reported in the literature to
be high, from 54 to 73% in some studies [31–33] but
often studies are using patient-reported outcome mea-
sures to assess prevalence, where CIPN prevalence is
not the primary objective. Even in our study, when
patient-reported outcome measures were used, preva-
lence doubled or tripled from that identified by other
measures. It remains to be seen if such measures are
appropriate diagnostic tools, as they also include
items related to autonomic changes; such changes
may have pre-existed the chemotherapy and it is un-
clear if they represent true CIPN-related changes or
they are unrelated symptoms, particularly as many of
the reporting studies are cross-sectional in nature. In
our data, about one-quarter of the patients reported
symptoms in the EORTC quality of life CIPN sub-
scales at baseline, before they received any chemo-
therapy (Table 3). Nevertheless, other studies show
similar results with our study including a one-year
cumulative prevalence of 28.7% [34], 23% in a sample
of patients receiving docetaxel [7] and 14.1% at 1 year
[35]. Thus, it is clear that if we focus on prevalence
rates that do not derive from patient-reported out-
come measures, then prevalence is generally lower to
about 15–25% of patients, the severity is generally
not high, and that patient-reported outcome measures
may overestimate CIPN prevalence as they include
symptoms that may have pre-existed the chemother-
apy. If patient-reported outcome measures, which are
generally used to assess the ‘impact’ of a symptom on
patients’ lives rather than diagnose a condition, are
used to show CIPN prevalence, it has to focus more
clearly on symptomatology that has developed after
the use of chemotherapy, and exclude those that had
similar symptoms before the chemotherapy. The latter
number we have seen in our study was as high as
21.2%. Hence, cross-sectional assessments of CIPN
using such patient-reported outcome measures can
overestimate its prevalence. Irrespective of prevalence
rates, however, the impact of the presence of such
symptoms is significant [4, 6–10, 36] and every effort
should be made to improve the patient symptom
experience.
The issue of reliable and valid measurement of
CIPN is fundamental, and based on the (relatively
low) correlations between scales shown in this study,
it may be that each scale measures a different
phenomenon or the scales used in this study were
not all sensitive enough to detect CIPN. Which scale
from the available ones is best for clinical assessment
remains to be identified, and perhaps there is a need
for a combination of scales to be used [37]. In our
study, the cotton wool assessment led to the lowest
‘pick up’ rates and at a later time from all other
scales suggesting this may not be an appropriate and
sensitive enough test. The WHO criterion and the
monofilament were highly correlated, suggesting that
the former measures more sensory changes. However,
the WHO criterion is minimally used in current prac-
tice. Abnormalities in vibration and monofilament ex-
aminations are associated with abnormal sural nerve
amplitudes [38] and hence monofilament may be a
useful method in identifying CIPN. The CTCAE is
the only scale that assesses separately motor and sen-
sory problems (alongside quality of life scales/
patient-reported outcome measures); while this is an
important dimension, in our study the CTCAE identi-
fied less patients with CIPN than other scales, sug-
gesting that it may not have high sensitivity.
Generally speaking, CIPN is not assessed properly
and we should focus more on improving its assess-
ment [6].
A recent review [39] suggests that CIPN is a pre-
dominantly sensory symptom with pain; however, in
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our study we obsered a considerable prevalence of
motor neuropathy, particularly in the docetaxel sub-
group, across assessments as well as paclitaxel and
paclitaxel/carboplatin in the later assessments. This
finding should be interpreted with caution as the only
motor neuropathy-specific scale we used was the
CTCAE item, and the literature suggests that the
CTACE motor item overestimates its occurrence, pos-
sibly as a result of confounding factors [40] although
NCS data confirms motor impairment in this sample
(suggested by the decreased motor nerve amplitude in
our sample). Also, it is unclear whether the motor
dysfunction observed is true motor neuropathy or fine
motor impairments secondary to sensory loss, which
is difficult to distinguish when ‘blunt’ instruments
such as the CTC are used. Motor dysfunction has
been shown in a small-scale study, where decreased
superexcitability of motor axons was reported [41].
Furthermore, a neurophysiological study in children
receiving vincristine showed impaired myotatic re-
flexes and motor neural impairment [42] and a larger
study in oxaliplatin-treated patients found no nerve
dysfunction before the initiation of chemotherapy [43]
while others studies (ie. ref. [38]) have focused on
sensory subclinical changes only. NCS focusing on
motor nerves, in addition to sensory nerves, could
a
b
c
Fig. 5 a. Chemotherapy-induced peripheral neuropathy
prevalence over time in patients receiving Docetaxel (n = 122,
901 assessments) b. Chemotherapy-induced peripheral
neuropathy prevalence over time in patients receiving Paclitaxel
(n = 33, 245 assessments) c. Chemotherapy-induced peripheral
neuropathy prevalence over time in patients receiving Cisplatin/
Carboplatin (n = 80, 409 assessments) d. Chemotherapy-induced
peripheral neuropathy prevalence over time in patients receiving
Oxaliplatin (n = 28, 200 assessments) e. Chemotherapy-induced
peripheral neuropathy prevalence over time in patients receiving
Carboplatin+Docetaxel (n = 29, 274 assessments) f.
Chemotherapy-induced peripheral neuropathy prevalence over
time in patients receiving Carboplatin+Paclitaxel (n = 49,
357 assessments)
d
e
f
Fig. 5 (Continued)
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highlight if the above comment is correct, and Kan-
dula et al. [44] review the diagnostic role of NCS in
CIPN. It may be that there is a general impression
that CIPN is mainly sensory impairment as most of
the studies in the past assessed sensory problems,
with little assessment of motor problems. Motor
symptoms may also be hidden under ‘fatigue’ too, and
‘feeling weak’ may be interpreted as tired rather than
myopathy. Also, it is common in clinical practice to
only ask patients if they have any numbness or
tingling in the hands/feet, again focusing only on sen-
sory symptoms. There is a need to focus more con-
cretely on the assessment of motor symptoms in the
future, as they are also linked with significant impact
in daily activities, and define CIPN more broadly as a
motor and sensory impairment accompanied by auto-
nomic system manifestations.
Furthermore, pain was not a major issue and oc-
curred in less than one-quarter of the participants,
whereas tingling and numbness were most prevalent
a
b
c
d
e
Fig. 6 a. Dose-response relationship related to NCI CTCAE-motor dysfunction scale with oxaliplatin, carboplatin (AUC), cisplatin, paclitaxel and
docetaxel respectively b. Dose-response relationship related to NCI CTCAE-sensory dysfunction scale with oxaliplatin, carboplatin (AUC), cisplatin,
paclitaxel and docetaxel respectively c. Dose-response relationship related to the WHO neuropathy scale with oxaliplatin, carboplatin (AUC),
cisplatin, paclitaxel and docetaxel respectively 6 d. Dose-response relationship related to cotton wool assessment with oxaliplatin, carboplatin
(AUC), cisplatin, paclitaxel and docetaxel respectively e. Dose-response relationship related to monofilament assessment with oxaliplatin,
carboplatin (AUC), cisplatin, paclitaxel and docetaxel respectively
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in more than half the sample. Pain may be more
prevalent in oxaliplatin [45, 46] or paclitaxel-based
chemotherapy but it seems to be less common in
other taxane- or platinum-based chemotherapies [47].
Whether autonomic symptoms are the result of CIPN
or symptoms reflecting other pre-existing conditions
before chemotherapy treatment is not clear as yet,
and more prospective work needs to be done in this
area too. Also, many other symptoms were reported
by patients at different degrees in each type of
chemotherapy suggesting that CIPN is not the same
symptom across taxanes and platins. This is an im-
portant finding to consider particularly when we as-
sess patients or when therapeutic trials for CIPN (in
terms of primary outcome) are planned.
At the 12-month assessment, a significant number
(around 8% through objective and physician-based
scales or 25–30% based on the patient-reported out-
come measure) remained with CIPN symptoms, simi-
lar or somewhat lower to other studies in the past [7,
Table 4 Odds ratios of the increased risk of developing neuropathy per 100 mg unit increase (or 1 AUC for carboplatin) of
chemotherapy dose (generalized estimating equation)
Abnormal
Drug NCI CTCAE motor NCI CTCAE sensory WHO CIPN Cotton wool Monofilament
Oxaliplatin-based regimens (n = 27, observations = 196) 1.15 (0.90, 1.47) 1.25 (0.94, 1.67) 1.13 (0.95, 1.34) 1.32* (1.06, 1.64) 1.42* (1.06, 1.89)
Carboplatin AUC (in 1 unit) (n = 88, observations = 657) 1.03 (0.98, 1.08) 1.06* (1.01, 1.10) 0.98 (0.93, 1.03) 0.93* (0.88, 0.99) 0.96 (0.92, 1.01)
Cisplatin-based regimens (n = 70, observations = 362) 0.89 (0.55, 1.46) 0.90 (0.55, 1.49) 1.43 (0.94, 2.19) 1.28 (0.57, 2.91) 1.37 (0.86, 2.17)
Paclitaxel-based regimens (n = 83, observations = 621) 1.02 (0.83, 1.25) 1.01 (0.85, 1.20) 1.01 (0.92, 1.11) 0.91 (0.80, 1.04) 0.94 (0.84, 1.06)
Docetaxel-based regimens (n = 151, observations = 1167) 0.96 (0.69, 1.32) 1.03 (0.69, 1.52) 1.36 (0.91, 2.04) 2.12 (0.93, 4.81) 1.47 (0.96, 2.25)
*Significant at 5% level
Fig. 7 Changes observed in chemotherapy-induced peripheral neuropathy through Nerve Conduction Studies. The graph values correspond to
the average of percentage differences to baseline (pre-NCS) of post-NCS and recovery-NCS
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34, 35, 48]. As CIPN has been seen in patients even
11–12 years after chemotherapy [10, 49], it seems that
this group of patients may experience chronic and
long-lasting CIPN.
Cumulative dose of the chemotherapy was not a pre-
dictive factor for CIPN, against the currently held belief,
in any of the chemotherapy regimens we assessed. An in-
creasing body of literature shows similar results [31, 50].
This brings into question the current practice [51, 52] of
dose reductions or chemotherapy discontinuation in pa-
tients experiencing CIPN. This finding, alongside with the
key factor of time since chemotherapy, suggests that from
the moment CIPN is experienced, it will continue to in-
crease for the next few months and carry its course before
we see any noticeable decreases after 6 months, irrespect-
ive of dose of chemotherapy [53], and patients may con-
tinue developing CIPN over time even if doses are
reduced [54]. Whether treatment discontinuation or dose
reductions have a real impact on decreasing CIPN should
be assessed in future research.
Limitations of the study include the decrease in the
sample over cycles (many patients did not complete
more than 3–4 cycles or were ill/dead, giving significant
missing data particularly in the 5th–6th cycle data. Some
chemotherapy protocols also had a relatively small sam-
ple size. Where numbers were small, results should be
interpreted with caution. Interrater reliability of the as-
sessments may be an issue, although specific training
and a protocol guide was provided to all assessors. The
sample from Caucasians was also small compared to the
Chinese and other Asian sample included. Some of the
assessments used (i.e. WHO criterion; cotton wool) have
not been rigorously evaluated as assessment methods in
the CIPN context) and hence interpretation of results
from these scales should be cautious. Cotton wool test
and 10 g monofilament can detect sensory impairment,
but they are unable to capture deep sensory impairment.
This is typical of platinum drugs neuropathy and might
partly explain why they are performing less efficiently
than tuning fork examination in comparison with litera-
ture data.
Conclusions
This study maps the development and progression of
CIPN in patients receiving taxane- and platinum-based
chemotherapy, showing distinct CIPN profiles. It shows
a lower level of CIPN than previously reported with sig-
nificant differences among different chemotherapy pro-
tocols and scales used to measure CIPN. It brings into
question the sensitivity and/or appropriateness of scales
currently used to measure CIPN. Nevertheless, CIPN is
a clinical problem present even 1 year after treatments
and needs careful clinical attention. Practice-important
findings include that early CIPN predicts CIPN in
subsequent cycles, and this is the case irrespective of cu-
mulative dose of chemotherapy. More work is needed in
ascertaining best assessment methods for clinical prac-
tice and the findings call for a re-think of current clinical
practices.
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